You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Based on full approval from the FDA based on the Phase III CROWN trial, Pfizer can now market the drug as a front-line option for ALK-positive NSCLC patients.
Under the deal, expected to close in April, Agilent will pay $550 million in cash on closing and up to an additional $145 million based on future milestones.
The partners will research the ability of Biocept's Target Selector molecular assay to determine EGFR status in non-small cell lung cancer patients.
Advanced NSCLC patients must have a PD-L1 expression tumor proportion score of 50 percent, and no EGFR, ALK, or ROS1 alterations, to receive the drug.
The researchers will compare saliva and plasma samples from 50 patients with non-small cell lung cancer to identify circulating tumor DNA in saliva.
The firms will use Resolution's ctDx liquid biopsy technology to find non-small cell lung cancer patients who may benefit from Mirati's KRAS G12C inhibitor therapy.
AmoyDx will develop and seek regulatory approval in China for a lung cancer PCR panel to be used with Merck's MET inhibitor tepotinib.
Oncocyte will receive upfront cash payments after transferring and installing DetermaRx, in addition to certain tests after it achieves inclusion in the US Comprehensive Cancer Network.
The firm will scale US-based testing capacity for its LiquidHallmark liquid biopsy assay, which uses amplicon-based technology to detect cancer-related mutations.
The company beat the consensus Wall Street estimate on the top line but narrowly missed it on the bottom line.